Biomarkers and Prognostic Tools

/Biomarkers and Prognostic Tools

Did You Know That Metastatic Prostate Cancer Causes DNA Mutations?

Men with metastatic prostate cancer have higher rates of inherited gene mutations than men with non-metastatic prostate cancer.  Knowing about DNA mutations might help you make better treatment decisions. And you can also tell family members about their risk. Recent studies have shown that metastatic prostate cancer inherited mutations in the DNA-repair genes, such as the BRCA gene, can help guide treatment decisions as well as increase cancer risk in their family members. These mutations are more common in men with metastatic prostate cancer compared with men whose prostate cancer hasn’t spread outside the prostate gland. Men with advanced, metastatic prostate cancer should ask to be [...]

By | January 3rd, 2017|biomarkers, BRACA1, BRCA2, Genetic testing, genetics, Uncategorized|0 Comments

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not respond to Xtandi or Zytiga and will live longer if treated with a taxane based chemotherapy (docetaxel) regimen. A study in JAMA Oncology, showed that evaluating for the presence of circulating tumor cells (CTCs) with AR-V7 could optimize treatment protocols. The study looked at 161 men with progressing metastatic castration-resistant [...]

In the 1990’s USA: PSA Screening Reduced Instances of Initial Diagnosis of Metastatic Prostate Cancer By 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis included only those men who had been diagnosed with advanced prostate cancer at diagnosis, not of early-stage disease that then progressed to metastasis. In this perspective study the authors describe trends in metastatic prostate cancer prior to and [...]

By | December 4th, 2016|advocacy, Biomarkers and Prognostic Tools, USPTF|0 Comments

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate cancer. The test evaluates the genetic makeup of tumor tissue taken from prostate biopsies. The Oncotype DX test has now been validated for adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death. According to a statement issued by Phil Febbo, M.D., the chief medical officer, Genomic Health, [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー